Cordis Announces Acquisition of MedAlliance
By acquiring MedAlliance, Cordis has the potential to serve two million patients globally by 2027 with the SELUTION SLR™ (Sustained Limus Release) drug-eluting balloon.
By acquiring MedAlliance, Cordis has the potential to serve two million patients globally by 2027 with the SELUTION SLR™ (Sustained Limus Release) drug-eluting balloon.